Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • In a day of losses on the ASX 200, Clinuvel’s share price has remained strong
  • The company announced a U.S. Food and Drug Administration review of its SCENESSE’s scientific dossier product has been slightly delayed
  • SCENESSE is designed to treat people with erythropoietic protoporphyria — a condition which makes skin hyper-sensitive to the sun
  • Clinuvel’s share price is up 4.07 per cent today, currently sitting at $25.80 apiece

Clinuvel shareholders are undeterred by a minor setback in receiving a U.S. Food and Drug Administration (FDA) review of the company’s SCENESSE product.

Going against today’s odds, which has seen over 80 per cent of ASX 200 companies in the red, Clinuvel has added over one dollar to its share price, recording a four per cent boost.

The pharmaceutical company’s SCENESSE is designed to assist people who have erythropoietic protoporphyria: a condition which leaves skin hyper-sensitive to the sun, causing pain or burning.

Clinuvel was firstly advised by the FDA its review date for SCENESSE’s scientific dossier under the Prescription Drug User Fee Act was set for October 6. Due to a miscommunication, the date is now set for October 8.

“Our team continues to engage with the FDA at this late stage to address final questions and clarifications on the dossier,” Clinuvel’s Chief Scientific Officer, Dr Dennis Wright, said.

“While it may be frustrating for all who take an active interest in our programs, nothing materially has changed in our outlook and we will continue our diligent approach in the coming days to seek a positive outcome,” Dr Dennis continued.

Shares in Clinuvel are currently trading at $25.80 apiece, as of 1:27 pm AEST.

CUV by the numbers
More From The Market Herald
CIMIC Group (ASX:CIM) - Chairman & CEO, Juan Santamaria

" CIMIC Group’s (ASX:CIM) CPB Contractors wins South Australia road contracts

CPB Contractors, a subsidiary of CIMIC Group (CIM), has been awarded road projects in South Australia.

" Watchdog sues Coles (ASX:COL) over staff underpayments

Coles (COL) has been accused of underpaying more than 7500 employees by $115 million between 2017 and 2020, according to an investigation by

" Macquarie Group (ASX:MQG) appoints former RBA Governor as new chair

Banking and financial services giant Macquarie Group (MQG) has appointed the former Governor of the Reserve Bank of Australia (RBA), Glenn Stevens, as
Woolworths Group (ASX:WOW) - CEO, Brad Banducci

" Woolworths (ASX:WOW) swoops on Wesfarmers’ (ASX:WES) API takeover (ASX:API)

Woolworths Group (WOW) has swooped on retail-competitor Wesfarmers (WES) takeover offer for Australian Pharmaceuticals Industries (API).